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doi:10.101Hematopoietic Cell Transplantation from an
HLA-Mismatched Familial Donor Is Feasible Without
Ex Vivo-T Cell Depletion after Reduced-Intensity
Conditioning with Busulfan, Fludarabine, and
Antithymocyte Globulin
Kyoo-Hyung Lee,1 Je-Hwan Lee,1 Jung-Hee Lee,1 Dae-Young Kim,1 Se-Hyung Kim,1
Ho-Jin Shin,2 Young-Shin Lee,1 Young-Ah Kang,1 Miee Seol,1 Sung-Gil Ryu1To extend the use of allogeneic hematopoietic cell transplantation (HCT) to patients without an HLA-
matched donor, we investigated HCT from a related donor with 1 fully mismatched HLA-haplotype after
conditioning with busulfan in reduced-dose, fludarabine, and antithymocyte globulin. Hematopoietic cells
were collected from the donors via leukapheresis after mobilization and infused without further manipula-
tion. Cyclosporin and methotrexate were administered for graft-versus-host disease (GVHD) prophylaxis.
Posttransplant engraftment, GVHD, and transplantation-related mortality (TRM) were recorded. Thirty-one
patients (age range: 16-69 years) with high-risk acute leukemia/myelodysplastic syndrome (n5 25) or bone
marrow failure (n5 6) were enrolled. The donors were either mothers (n5 14), offspring (n5 9), or siblings
(n5 8) of these patients. Excluding 3 patients who died or relapsed with leukemia within 3 weeks after HCT,
all the remaining 28 patients engrafted with neutrophils (.500/mL) at a median of 16.5 days. Twenty-two of
24 evaluated patients achieved complete donor chimerism ($95%) 2 weeks after HCTand none experienced
graft failure subsequently. The cumulative incidences of grade 2-4 acute GVHD (aGVHD) and moderate-
severe chronic GVHD (cGVHD) were 19% (95% confidence interval [CI], 9%-40%) and 20% (95% CI,
10%-41%), respectively. After a median follow-up of 18.2 months (range: 6.3-52.1), 18 patients remained alive
(53%). Four patients died without recurrence/progression of underlying diseases giving a TRM of 13% (95%
CI, 5%-33%). HCT from an HLA-mismatched family member is feasible without ex vivo T cell depletion when
reduced-intensity conditioning containing anti-hymocyte globulin is performed.
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nancies and bone marrow failure syndrome. Wider
application of this procedure, however, is impeded by
limited donor availability [1]. Less than one-third of pa-
tientswho require allogeneicHCThave ahuman leuko-
cyte antigen (HLA)-matched family member who can
donate hematopoietic cells. HLA-matched unrelated
donors can be found for patients who do not have an ap-
propriate donor unless these patients carry rare or pri-
vate HLA-haplotype; however, significant time delays
(3-5months) and additional costs are associated [2].Un-
related umbilical cord blood transplantations may be
considered forpatientswithout anHLA-matched famil-
ial or unrelated donor available, but the smaller number
of hematopoietic cells in these graft can result in delayed
engraftment or eventual graft failure [3].
Nearly all patients who are in need of allogeneic
HCT have at least 1 HLA-haploidentical family61
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immediately, not only for the initial transplantation,
but also for any additional donations that may be nec-
essary [4]. Early attempts to transplant allogeneic he-
matopoietic cells across the HLA-haplotype barrier
result in high frequencies of engraftment failure and
severe graft-versus-host disease (GVHD) [5,6]. Deple-
tion of donor T cells from the grafts prior to HCT de-
creases the frequency and severity of GVHD, but it
results in increased graft failure, delayed immune re-
constitution, and increased fatal infections [7,8]. In-
duction of specific donor T cell anergy against host
tissue has been attempted in a small number of patients
[9]. Recent efforts to improve the outcomes of HLA-
mismatched family donor HCT have included trans-
plantation of higher dose of purified CD341 cells
[10], the use of polyclonal [11,12] or monoclonal
[13,14] antibodies against T cells as a part of the con-
ditioning regimen (in vivo T cell depletion), and incor-
poration of the concept of feto-maternal immune
tolerance in selecting donors from among several
available HLA-mismatched family members [15]. De-
spite these efforts, HCT from an HLA-mismatched
family member remains a procedure that is associated
with high regimen-related toxicity and high transplan-
tation-related mortality (TRM) ranging from 20% to
40% [10,11,15].
In addition to the aforementioned approaches, re-
duced-intensity conditioning (RIC) may be effective in
the setting of HLA-mismatched family donor HCT.
Various RIC regimens, utilizing total-body irradiation
(TBI) [16], busulfan [17,18], or melphalan, along with
fludarabine, have been shown effective in achieving
successful engraftment with a reduced frequency of
TRM, particularly in elderly patients and in patients
with organ dysfunctions, for HCT from both HLA-
matched siblings and unrelated donors. These findings
showed that, under conditions of adequate immuno-
suppression of the patient, but not necessarily myeloa-
blation, donor hematopoietic cells can engraft and
a complete donor hematopoietic chimerism can be
achieved. The same principle may be extended to
HLA-mismatched HCT settings. In fact, successful
engraftment of allogeneic hematopoietic cells across
HLA-haplotype differences after RIC has been ob-
served in animal models [19-21], in infants with severe
combined immunodeficiency syndrome [22,23], and in
adult patients with hematologic malignancies using
heterogeneous RIC regimens [24-29]. Furthermore,
the beneficial effects of RIC in a HLA-haploidentical
HCT setting may include decreased acute GVHD
(aGVHD) and TRM, as has been shown in a swine
leukocyte antigen (SLA)-haploidentical transplanta-
tion model [19]. Low frequencies of aGVHD (grade
2-4 of 16% to 20%) have been reported in adult
patients with hematologic malignancies after HLA-
mismatched HCT after RIC [28,29]. These findingsindicate the need to further investigate the role
of RIC in HLA-mismatched familial donor HCT.
We therefore investigated the feasibility of HLA-
mismatched familial donor HCT in patients with
high-risk hematologic disorders after conditioning
with busulfan in reduced-dose, fludarabine, and an-
tithymocyte globulin (ATG), an RIC regimen based
on the original regimen developed by Slavin et al
[17]. Similar RIC regimens, including oral busulfan,
fludarabine, and ATG, have been used in an HLA-
mismatched HCT setting by Ogawa et al [28]. The
hematopoietic cells were obtained from the donor via
peripheral blood after mobilization with granulocyte
colony-stimulating factor (G-CSF) and no ex vivo
T cell depletion was performed from the graft.METHODS
Patients and Hematopoietic Cell Donors
An allogeneic HCT protocol for patients with
high-risk hematologic disorders, utilizing an HLA-
mismatched family member as the donor, was initiated
in April 2004. Thirty-one patients (20 males, 11 fe-
males; median age: 34 years [range: 16-69 years]; sum-
marized in Table 1) were enrolled before April 2008.
All patients were unable to find suitable HLA-matched
hematopoietic cell donors in their families or from the
donor registries. At study entry, 21 patients were
deemed not suitable as candidates for myeloablative
conditioning for HCT because of; age $50 years
(n 5 4), previous allogeneic HCT (n 5 6), immediate
prior exposure to salvage chemotherapy including in-
termediate/high-dose ara-C (n5 9), and the poor gen-
eral condition (n5 2; UPNs 495 and 618). All patients
in the study also met the following entry criteria: age of
15 to 75 years; diagnosis of high-risk acute leukemia
(acute leukemia in the first complete remission [CR]
but with high-risk chromosomal changes/after salvage
or in over first CR); high-risk myelodysplastic syn-
drome (MDS) (ie, refractory anemia with excess
blasts-1, -2, or chronic myelomonocytic leukemia),
or bone marrow failure syndrome (severe aplastic ane-
mia or low-risk myelodysplastic syndrome, that is, re-
fractory anemia or refractory cytopenia with
multilineage dysplasia) with failure to respond or re-
current cytopenia after treatment with ATG or hypo-
methylating agents; a Karnofsky performance scale
$70; and adequate organ function (total bilirubin
\2.0 mg/dL, aspartate aminotransferase [AST]\120
U/L, creatinine \2.0 mg/dL, and cardiac ejection
fraction .45% by multigated blood pool scan).
HLA-A, -B, -C, and -DR typing of the patients was
performed using PCR sequencing-based methods,
and of the family members was determined by sero-
logic methods or by PCR. All patients had at least 1
family member, aged 70 years or less, who were
Table 1. Patient andDonor Characteristics from aGroup InvolvingHematopoietic Cell Transplantations from anHLA-Mismatched Familial Donor after Reduced-Intensity Conditioning
with Busulfan, Fludarabine, and Antithymocyte Globulin
UPN Age/ Sex
Dx, Status of
Disease at HCT
Months from
Dx to HCT Treatment Prior to HLA-Mismatched HCT Donor, Age
HLA Disparity Graft Cell Dose, by
GVH Rejection
MNC
(108/kg)
CD3+
(108/kg)
CD34+
(106/kg)
346 16/M ALL, Ph+, CR2 17 VPDL plus imatinib induction, consolidation (x7); IT MTX plus AC for
leptomeningeal recurrence
Mother, 42 3/6 2/6 8.7 4.7 73.5
358 43/F AML M4, Rel1 14 AD induction, HDAC consolidation (x4); CME salvage Daughter, 18 2/6 3/6 3.7 1.8 7.1
359 34/M AmixL, CR1 5 AD induction, HDAC consolidation (x2) Mother, 61 2/4 2/4 8.0 3.8 5.9
390 20/M MDS RCMD 7 ATG plus cyclosporine Mother, 44 3/6 3/6 7.1 5.0 6.8
395 22/F MDS RA 80 ATG Mother, 62 1/6 2/6 10.2 5.6 6.7
431 24/M AML M0, CR2 25 AD induction, HDAC consolidation (4), U-HCT; AD salvage Mother, 45 3/6 3/6 6.1 4.7 7.0
435 34/M SAA 107 ATG plus cyclosporine; U-HCT Mother, 55 2/6 1/6 6.0 4.6 4.5
446 16/M ALL, T cell, Rel2 11 VPDL induction, consolidation (2); CVAD salvage, IT AC for
leptomeningeal leukemia
Mother, 45 3/6 3/6 8.6 5.2 10.5
454 25/M AML M2, CR2 19 AD induction, HDAC consolidation (4); FLAG salvage Mother, 48 2/6 2/6 6.6 4.0 4.7
463 21/M SAA 22 ATG plus cyclosporine Mother, 49 3/6 2/6 7.4 4.5 10.6
465 19/F AML M0, CR1(s) 9 AD induction and reinduction; FLAG-idarubicin salvage Mother, 48 3/6 2/6 11.1 5.4 18.0
479 28/M CMMoL, Ref 33 FLAG chemotherapy; CME chemotherapy; U-HCT Sister, 26 3/6 3/6 6.2 4.7 6.1
PNU 26/F ALL, pre-B, CR2 65 VPDL induction, consolidation (8), maintenance; VPDL salvage Mother, 48 2/6 3/6 8.0 3.4 7.9
495 48/M MDS RAEB-1 7 Oxymetholone; corticosteroids and antimicrobials for intractable myositis Son, 19 3/6 3/6 7.8 4.6 3.6
518 22/M AML M1 CR2 24 AD induction, HDAC consolidation (3), U-HCT; AD salvage Mother, 49 3/6 2/6 6.7 3.5 5.2
523 48/F AML M4, Ref 25 AD induction and re-induction Son, 17 3/6 3/6 8.7 4.4 28.4
528 50/M AML M2 Rel2 21 AD induction, HDAC consolidation (4); AD salvage Daughter, 23 3/6 3/6 9.8 6.0 3.6
546 27/M ALL, NK cell, Ref 31 VPDL induction, consolidation (3), U-HCT; CVAD salvage plus DLI;
CODOX-M salvage; HDAC plus idarubicin salvage; IT MTX
Mother, 53 3/6 3/6 4.5 2.8 4.6
549 38/F AML M1, CR1(s) 5 AD induction and re-induction; FLAG salvage; CME salvage Brother, 38 3/6 3/6 12.1 8.5 27.7
551 65/F AML M1, CR2 12 AD induction, AD consolidation (2); FLA salvage, FLA consolidation (1) Son, 39 2/6 3/6 10.4 5.5 15.0
568 23/M MDS RCMD 8 Azacytidine (5) Mother 43 2/6 3/6 6.9 4.1 5.1
576 52/F AML M2, Ref 9 AD induction, HDAC consolidation (1); AD salvage Son, 24 2/6 3/6 13.1 8.8 17.7
582 41/M AML M2, Ref 15 AD induction, HDAC consolidation (4); FLA-Ida salvage (2) Brother, 36 3/6 3/6 7.0 4.7 8.2
590 25/F AML M1, CR2 16 AD induction, HDAC consolidation (4); FLAG-Ida salvage Sister, 26 2/6 2/6 10.1 7.9 2.9
592 36/M AML M4, Ref 10 enocitabine plus idarubicin for induction; salvage with mylotarg, cytarabine,
mitoxantrone, and fludarabine
Brother, 35 2/6 2/6 5.7 3.9 8.2
593 36/F AML M2, Ref 18 AI induction, HDAC consolidation (4); AD salvage ; CME salvage Son, 3 3/6 1/6 5.2 3.6 1.3
606 45/M AML M1, Ref 3 AD induction and reinduction Brother, 51 3/6 3/6 6.1 1.5 5.5
612 40/M ALL, pre-B, Ref 7 VPDL induction, consolidation (1); CODOX-M salvage ; CME salvage Brother, 43 1/6 1/6 7.0 4.7 5.7
615 69/M MDS, RAEB-2 6 Azacytidine (x6) Son, 36 3/6 3/6 8.1 5.5 5.8
617 50/F MDS, RAEB-1 8 HCT from an HLA-matched sibling Daughter, 26 2/6 1/6 7.5 4.5 11.7
618 31/M MDS, RCMD 154 Corticosteroids and antimicrobials for necrotic dermatitis; azacytidine (6) Sister, 35 1/6 1/6 7.6 4.7 6.9
UPN indicates unique patient number; Dx, diagnosis; HCT, hematopoietic cell transplantation; RBC, red blood cells; GVH, graft-versus-host direction; MNC, mononuclear cells; M, male; F, female; Ph+, Philadelphia
chromosome positive; ALL, acute lymphoblastic leukemia; CR2, second complete remission; VPDL, vincristine, prednisolone, daunorubicin, and L-asparaginase; IT, intrathecal; MTX, methotrexate; AC, ara-C; AML,
acute myeloid leukemia; Rel1, first relapse; AD, ara-C and daunorubicin; HDAC, high-dose ara-C; CME, ara-C, mitoxantrone, and etoposide; AmixL, acute mixed lineage leukemia; CR1, first complete remission; MDS,
myelodysplastic syndrome; RCMD, refractory cytopeniawithmultilineage dysplasia; ATG, antithymocyte globulin; RA, refractory anemia; U-HCT, unrelated donor hematopoietic cell transplantation; SAA, severe aplas-
tic anemia; Rel2, second relapse; CVAD, cyclophosphamide, vincristine, adriamycin, and dexamethasone; FLAG, fludarabine, ara-C, and granulocyte colony-stimulating factor; CR1(s), first complete remission after
salvage chemotherapy; CMMoL, chronic myelomonocytic leukemia; Ref, refractory disease; PNU, Pusan National University Hospital case; RAEB-1, refractory anemia with excess blast-1; NK, natural killer;
CODOX-M, cyclophosphamide, vincristine, adriamycin, and methotrexate; FLA, fludarabine and ara-C; FLA-ida, fludarabine, ara-C, and idarubicin; RAEB-2, refractory anemia with excess blast-2.
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64 Biol Blood Marrow Transplant 15:61-72, 2009K.-H. Lee et al.mismatched at 1 to 3 of 6 HLA-A, -B, and -DR loci. If
a patient had several HLA-mismatched family mem-
bers, attempts were made to select a donor based on
the concept of feto-maternal immune tolerance [15].
Twenty-one patients received a graft from donors
with potential feto-maternal immune tolerance to
these patients. These included 14 patients who re-
ceived grafts from their mothers (median age: 48 years;
range: 42-62 years; Table 1), 6 female patients who re-
ceived grafts from offspring, and 1 patient who re-
ceived a graft from a sister with a mismatched
maternal HLA-haplotype. Three male patients re-
ceived grafts from their offspring, thus without the
possibility of feto-maternal immune tolerance between
the patient and the donor. In 7 patient-donor pairs, the
origin of themismatchedHLA-haplotype could not be
determined because of an inability to perform parental
HLA typing. The HCT treatment protocol was
approved by the institutional review boards of the
Asan Medical Center and Pusan National University
Hospital, and is listed on theNational Cancer Institute
(Bethesda, MD) clinical trial registry at www.cancer.
gov as #NCT00521430. All patients and donors
participating in the study provided written informed
consent.Transplantation Procedure
The conditioning regimen consisted of busulfan
(Busulfex, Orphan Medical Inc., Minnetonka, MN)
3.2 mg/kg/day intravenously (i.v.) on days 27 and 26
ofHCT (day 0, the first day of donor cell infusion), flu-
darabine 30mg/m2/day i.v. on days27 to22, and rab-
bit ATG (Thymoglobulin [Genzyme Transplant,
Cambridge, MA]) 3 mg/kg/day i.v. on days 24 to 21.
Three patients transplanted in 2005 received horse-
ATG (Lymphoglobulin [Genzyme Transplant])
15 mg/kg/day instead of rabbit ATG. Methylprednis-
olone 2 mg/kg was given i.v. 30 minutes prior to the
daily infusions of ATG.
Starting on day23, each hematopoietic cell donor
was given G-CSF 10 mg/kg subcutaneously daily for 4
to 5 days. Donor mononuclear cells were harvested by
large-volume leukapheresis starting on the fourth day
(day 0 ofHCT) of G-CSF administration. The interim
goal was to harvest at least 5 106 CD341 cells per ki-
logram of recipient body weight. The collected cells
were administered to the patients through central ve-
nous catheters on the same day. Twenty-three donors
in the study underwent 2 daily cell collections (days
0 to1), whereas the remaining 7 and 1 donors required
3 and 4 collections, respectively. Eleven patients who
enrolled in the study after May 2007 were also partic-
ipants in a separate phase 1 clinical trial, in which each
was planned to be given an additional infusion of do-
nor CD341 cell-derived natural killer (NK) cells about
6 weeks after HCT. Hence, the donors for these 11patients underwent an extra day of cell collection after
an extra dose of G-CSF.
For GVHD prophylaxis, cyclosporine 1.5 mg/kg
was given i.v. every 12 hours starting on day 21,
then switched to an oral dose of 2 to 3 times the i.v.
dose subsequently. The cyclosporine blood levels
were referenced to 100-300 ng/mL. In the absence of
acute GVHD, cyclosporine dose was tapered begin-
ning 30 days after HCT. In addition, patients received
methotrexate 15 mg/m2 i.v. 1 day after the last donor
cell infusion; and 10 mg/m2 3, 6, and 11 days after
the last donor cell infusion. In 18 patients, the last
dose of methotrexate was omitted because of oral mu-
cositis (n 5 16) or elevated liver transaminase (n 5 2).
Supportive care for the patients included diphenyl-
hydantoin i.v. during busulfan administration, cipro-
floxacin and fluconazole orally, commencing with
conditioning therapy, and G-CSF 450 mg i.v. infusion
daily starting on day 5 of HCT. Ciprofloxacin, fluco-
nazole, and G-CSF were given until absolute neutro-
phil count (ANC) recovered to 3000/mL. Gamma
globulin 0.5 g/kg was given i.v. on the day of initiation
of conditioning therapy, biweekly until day 91 of
HCT, and monthly until day 180. Cytomegalovirus
(CMV) pp65 antigenemia was assayed weekly until
day 100 with preemptive ganciclovir treatment when
appropriate.Evaluations
The first days of ANC over 500/mL for 2 consecu-
tive days and the first days of unsupported platelet
count over 20,000/mL for 7 consecutive days were re-
corded for neutrophil and platelet engraftments, re-
spectively. Bone marrow examination was performed
on the day prior to conditioning therapy and 4 to 6
weeks after HCT. CR was defined as the recovery of
a peripheral blood ANC over 1000/mL and a bone
marrow aspirate showing donor cell regeneration
with 5% or fewer blasts. Recurrence was defined as
the presence of leukemic blasts in the bone marrow
(over 5%) in patients with a previously documented
CR. In patients with persistent leukemia after HCT,
the day of progression of leukemia was defined as the
day when leukemic blasts reappeared in the peripheral
blood with bone marrow examination showing persis-
tent blasts over 5%. Acute GVHD and chronic
GVHD (cGVHD) were diagnosed and graded accord-
ing to previously published criteria [30,31]. A poly-
merase chain reaction (PCR)-based procedure
utilizing short tandem DNA repeats (STR) was used
to analyze hematopoietic chimerism 2, 4, 6, 8, 12,
and 24 weeks after HCT. Blood lymphocyte subset
counts (CD31, CD41, CD81, and CD161/561)
were measured at the time of initiation of conditioning
therapy, as well as 1, 2, 3, 6, and 12 months after HCT.
Biol Blood Marrow Transplant 15:61-72, 2009 65HLA-Mismatched HCTafter RIC Containing ATGStatistics
The purpose of our study was to examine the fea-
sibility of HCT from an HLA-mismatched familial
donor without ex vivo depletion of donor T cells after
RIC with busulfan, fludarabine, and ATG. The pri-
mary endpoints of the study were the occurrence of
posttransplant donor cell engraftment, GVHD, and
TRM. Times to engraftment, aGVHD and cGVHD,
and TRM were measured from HCT and estimated
using the cumulative incidence function [32]. For en-
graftment and aGVHD and cGVHD, the recur-
rence/progression of underlying disease or the death
were considered as competing risks. For TRM, death
without recurrence or progression of underlying dis-
ease was considered as an event, whereas disease recur-
rence or progression was considered as a competing
risk. Overall survival (OS) was measured from HCT
to death or last follow-up. Event-free survival (EFS)
was measured from HCT to disease recurrence/pro-
gression, death without disease, or last follow-up. An
interim analysis performed after the 10th patient was
enrolled, as per an institutional review board recom-
mendation, showed an acceptable neutrophil engraft-
ment (90%) and 100-day TRM (10%).RESULTS
Disease and Graft Characteristics
The demographic characteristics of each patient
and donor, as well as the characteristics of the underly-
ing disease of each patient are summarized in Table 1.
Twenty-one patients had acute leukemia, 4 had high-
riskMDS, 4 had low-riskMDS, and 2 had severe aplas-
tic anemia. The disease status of acute leukemia at the
time of transplantation was the first CR in 1, the first
CR after salvage chemotherapy in 2, the second CR
in 7, and refractory or recurrent leukemia in 11.
In 29 donor-patient pairs, there were 2 to 3 dispar-
ities of the 6 HLA A-, B-, DR-antigens either in the
graft-versus-host (GVH) or in rejection directions.
In 17 donor-patient pairs (55% of the cohort), there
were 3 disparities in both GVH and rejection direc-
tions. Two donor-patient pairs had 1 antigen disparity
for both the GVH and rejection directions. In these 2
donor-patient pairs, however, PCR-based typing re-
vealed 2 disparities among 8 HLA A-, B-, C-, and
DR-antigens in both directions. The median number
of mononuclear cells transplanted was 7.5  108
(range: 3.7-13.1  108)/kg of recipient body weight,
the median number of CD341 cells transplanted was
6.8  106 (range: 1.3-73.5  106)/kg, and the median
number of donor CD31 cells infused was 4.7  108
(range: 1.5-8.8  108)/kg. All 31 patients and 30 cell
donors in this study showed a positive IgG serology
for CMV.Engraftment and Posttransplant Chimerism
The clinical courses of the patients after HCT are
summarized in Table 2. The RIC regimen with busul-
fan, fludarabine, and ATG was well tolerated. On the
first day of ATG infusion all patients had varying de-
grees of fever, anorexia, and myalgia, which were re-
duced on subsequent days. A skin rash lasting several
days was observed in 10 patients. One patient (UPN
606) did not receive the second daily dose of ATG be-
cause of a high fever and hypotension. Four patients
experienced reversible hepatic dysfunction with peak
total bilirubin levels ranging 2.3-6.7 mg/dL.
Three patients in this study failed to show neutro-
phil engraftment. Two patients, who had experienced
secondary graft failure after a previous allogeneic
HCT, died on days 5 and 18 after HLA-mismatched
familial donor HCT because of sepsis. Another patient
(UPN 593) showed early progression of leukemia with
increasing leukemic blasts in the peripheral blood 8
days after HCT. All of the 28 other patients achieved
donor cell engraftment with ANC over 500/mL me-
dian 16.5 days (range: 11-53 days; cumulative inci-
dence, 90%; 95% confidence interval [CI], 81% to
100%; Figure 1A), whereas 26 of 28 patients achieved
a platelet count over 20,000/mLmedian 23 days (range:
12-100 days; cumulative incidence, 84%; 95% CI,
72% to 98%). None of these patients experienced sec-
ondary graft failure.
Hematopoietic chimerism was assessed in the pe-
ripheral blood mononuclear cells. Excluding patients
with persistent or recurrent leukemia with circulating
leukemic cells in the peripheral blood (UPNs 446
and 593 from 2 weeks after HCT; and UPNs 358
and 479 from 8 weeks; Table 2), 22 of 24 evaluated pa-
tients showed complete donor chimerism (donorDNA
$95%) as early as 2 weeks after HCT. By 4 weeks after
HCT, all 25 evaluated patients showed complete
donor chimerism, which was maintained until 24
weeks after HCT in all of the subjects who were tested
(Table 2).GVHD and Posttransplant Infections
The frequencies of aGVHD and cGVHD ob-
served in our study were not excessive (Table 2). Al-
though the number of cases was limited, there was
no unusual feature in the clinical manifestations and
treatment outcomes in GVHD observed in our study
(Table 3). Acute GVHD of all grades occurred in 8 pa-
tients (cumulative incidence, 26%; 95% CI, 14% to
47%; Figure 1B) between 9 and 39 days after HCT.
Grades 2 to 4 aGVHD occurred in 6 patients (cumu-
lative incidences, 19%; 95% CI, 9% to 40%) while
grade 3 to 4 aGVHD occurred in 3 patients (cumula-
tive incidence, 10%; 95% CI, 3% to 28%). One pa-
tient developed grade 4 aGVHD and died on day
136 because of sepsis associated with intractable
Table 2. Outcomes of Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor after Reduced-Intensity
Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin
UPN
Marrow Recovery
(Days after HCT)
Acute
GVHD
Chronic
GVHD
Posttransplant Hematopoietic
Chimerism (Recipient DNA Percentage)
Disease
Recurrence/
Progression
(Months
after HCT)
Current Status
(Months after HCT)
ANC >
500/mL
Platelet
>20,000/mL 2 wks 4 wks 6 wks 8 wks 12 wks 24 wks
346 15 22 None Mild 0 0 0 0 0 0 Yes (7.4)* Died (11.1)
358 15 39 None — 0 <5 0 30 40 Yes (2.9)† Died (4.1)
359 18 21 Gr 1 Mild 0 0 0 0 0 0 Alive and well (52.1)
390 18 16 None None 0 0 0 0 0 0 Alive and well (46.7)
395 17 24 Gr 3 Severe 0 — 0 0 0 0 Alive with lung GVHD (45.5)
431 13 25 None None 0 0 0 0 0 0 Yes (2.2)‡ Alive with leukemia (38.5)
435 — — — — ND Died because of K. pneumoniae
sepsis (0.6)
446 12 — Gr 2 — 15 80 — — — — Yes (1.1) Died with leukemia (1.3)
454 16 17 Gr 2 Severe 0 0 0 0 0 0 Alive and well (34.8)
463 27 100 Gr 3 Moderate 0 0 0 0 0 0 Alive and well (33.4)
465 17 28 None None 0 0 0 0 0 Yes (4.0)§ Died (6.0)
479 53 60 None None <5 5 0 50 10 0 Yes (2.4)¶ Died (12.5)
PNU 13 12 Gr 1 Mild ND <5 <5 <5 <5 <5 Yes (15.2) Died with leukemia (16.2)
495 18 25 Gr 4 None 20 0 0 0 0 — Died because of acute GVHD (4.5)
518 17 13 None None 0 0 0 0 0 0 Alive and well (22.2)
523 15 23 None None 0 0 0 0 0 0 Alive and well (21.0)
528 14 21 None Moderate 0 0 0 0 0 0 Yes (14.4)** Alive in CR3 (20.1)
546 17 37 Gr 2 — <5 5 0 Yes (1.9) Died with leukemia (4.9)
549†† 23 23 None None 0 0 0 0 0 0 Yes (11.5) Alive with leukemia (16.4)
551†† 18 18 None None ND 0 0 0 0 0 Alive and well (15.7)
568†† 21 30 None None ND 0 0 0 0 0 Alive and well (12.6)
576†† 11 14 None Severe 0 0 0 0 0 0 Yes (11.6) Alive with leukemia (11.7)
582†† 17 29 None None 0 0 0 0 0 Yes (6.7)‡‡ Alive in CR3 (10.8)
590†† 15 17 None None <5 0 0 0 0 0 Alive and well (9.9)
592†† 16 16 None — <5 0 60 Yes (1.5) Died (1.7)
593 — — — — 75 <5 <5 70 Yes (0.4)§§ Died (3.3)
606†† 16 22 None Moderate 0 0 0 0 0 0 Alive and well (8.2)
612 16 24 None — 0 Died because of sepsis (0.9)
615 15 — None None 0 0 0 <5 <5 Yes (2.3) Alive with MDS (6.8)
617 — — — — ND Died because of S. maltophilia
sepsis (0.2)
618†† 23 28 None — 45 0 0 0 0 0 Alive and well (6.3)
UPN indicates unique patient number; HCT, hematopoietic cell transplantation; wks, weeks after transplantation; ANC, absolute neutrophil count;
GVHD, graft-versus-host disease; Gr, grade; CR3, third complete remission status; PNU, Pusan National University Hospital case; MDS, myelodysplastic
syndrome.
*After recurrence, treatment with imatinib 600mg daily was initiated, and the patient achieved hematologic CR. Subsequently, the patient received a do-
nor leukocyte infusion (0.77 108 CD3+ cells/kg). Unfortunately, the patient died 3 months later with severe gastrointestinal graft-versus-host disease.
†After recurrence, prophylactic cyclosporine was discontinued. Subsequently, because of the lack of a response, a donor-leukocyte infusion (2.87 108
CD3+ cells/kg) was given. The peripheral blood blast persisted, and the patient died 17 days later with cytopenia and sepsis.
‡Initially, prophylactic cyclosporine was discontinued. Sixteen days later, the patient developed a generalized skin rash and achieved CR. The patient
remained in CR for over 2 years until a second disease recurrence. This patient again achieved CR after salvage chemotherapy with fludarabine, cytar-
abine, and idarubicin and, subsequently, underwent a third allogeneic HCT from an HLA-mismatched brother. Unfortunately, leukemia recurred third
time 13 months after his second haploidentical HCT.
§Initially, prophylactic cyclosporinewas discontinued. Because of the lack of a response, 3 donor-leukocyte infusions were given (2.2 108 CD3+ cells/kg
in total). Twenty-seven days after the last infusion, the patient died with generalized skin rash, cytopenia, and sepsis.
¶After discontinuation of prophylactic cyclosporine, the patient was given a donor-leukocyte infusion (0.6  108 CD3+ cells/kg) and achieved CR. Un-
fortunately, the patient died 10 months later because of GVHD (cytopenia, weight loss, and recurrent infections).
**The patient received salvage chemotherapy with cytarabine, fludarabine, and idarubicin and achieved CR. Subsequently, the patient underwent a sec-
ond allogeneic HCT from another HLA-mismatched familial donor (daughter).
††As part of a phase 1 study, 9 patients in this study received donor CD34+ cell-derived natural killer cells [median dose 8.8 (range, 0.3-12.9)  106/kg
cells] 6 weeks after HLA-mismatched familial donor HCT. No acute toxicity or GVHD was observed in none of these patients after the infusion.
‡‡The patient received salvage chemotherapy with cytarabine, mitoxantrone, and etoposide but failed to achieve CR. Subsequently, the patient under-
went a second allogeneic HCT from another HLA-mismatched familial donor (son) and achieved CR3.
§§After discontinuation of prophylactic cyclosporine, leukemic blasts disappeared from the peripheral blood. However, bone marrow examination
showed persistent leukemia.
66 Biol Blood Marrow Transplant 15:61-72, 2009K.-H. Lee et al.diarrhea and liver failure, which was the only GVHD-
related death observed in our study. Chronic GVHD
was observed in 9 patients (cumulative incidence,
30%; 95%CI, 18% to 52%; Figure 1C), while moder-
ate to severe cGVHD by National Institutes of Health(NIH) criteria was observed in 6 patients (cumulative
incidence, 20%; 95% CI, 10% to 41%).
Twenty patients in this study showed at least 1 pos-
itive CMV antigenemia assay between days 16 and 62
of HCT; and 13 of those required preemptive
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Figure 1. Cumulative incidence estimates of (A) donor cell engraftment and (B) aGVHD and (C) cGVHD observed after HLA-mismatched familial
donor HCT following RIC with busulfan, fludarabine, and ATG.
Biol Blood Marrow Transplant 15:61-72, 2009 67HLA-Mismatched HCTafter RIC Containing ATGganciclovir treatment (Table 4). Two patients (UPNs
454 and 463) developed CMV colitis, but both re-
covered. Other significant infections observed after
HLA-mismatched HCT in our study were cutaneous
varicella-zoster virus infections (n 5 7), sepsis (n 5 6),
and pneumonia (n5 5; including 1 because of Pneumo-
cystis carinii).
Patient Survival and TRM
After a median follow-up of surviving patients of
18.2 months (range: 6.3-52.1 months), 18 patientsTable 3. Clinical Characteristics and TreatmentOutcomes of Acute
Who Underwent Hematopoietic Cell Transplantation from an HLA
tioning With Busulfan, Fludarabine, and Antithymocyte Globulin
UPN
Acute GVHD
Grade
Onset
(Day)
Involved
Organs
(Stage)
Systemic
Treatment Outcomes
346 — — — — —
359 1 39 Skin (2) pCS, GCS Resolved
395 3 15 Skin (3) pCS, GCS, Resolved
Gut (2) MMF
446 2 9 Skin (3) pCS, GCS Resolved
454 2 14 Skin (3) pCS, GCS Persisted to
Gut (1) chronic
GVHD
463 3 20 Liver (1) pCS, GCS, MMF,
octreotide
Persisted to
chronic GVHDGut (3)
PNU 1 14 Skin (2) pCS, GCS Resolved
495 4 35 Skin (3) MMF, GCS, FK506 Death because
of liver failure
and sepsis
Liver (4)
Gut (4)
528 — — — — —
546 2 17 Skin (2) FK506, GCS Resolved
576 — — — — —
606 — — — — —
UPN indicates unique patient number; GVHD, graft-versus-host disease; pCS, c
cyclosporine; MMF, mycophenolate mofetil; IST, immunosuppressive treatmenwere alive (OS, 53%). Of the 10 patients who were
transplanted for acute leukemia in the first or second
CR, 7 remained alive (OS, 63%; Figure 2A), and of
these cases, 5 showed no recurrence (EFS, 47%;
Figure 2B). Of the 15 patients who were transplanted
for refractory acute leukemia or high-risk MDS, 7
achieved CR after HCT and 2 maintained this state
for 8.2 and 21.0 months. The OS and EFS for this
group of patients were 31% and 9%, respectively. Six
patients were transplanted for bone marrow failure
syndrome and 5were alive and showing a goodmarrowand Chronic Graft-versus-Host DiseasesObserved in Patients
-Mismatched Familial Donor after Reduced-Intensity Condi-
Chronic GVHD
NIH Score
Onset
(Day)
Involved
Organs
Systemic
Treatment Outcomes
Mild 117 Mouth pCS, GCS Resolved
Mild 115 Mouth None Resolved
Severe 76 UGI- pCS, GCS Resolved
289 diarrhea CS, GCS Resolved
716 Mouth-skin CS, GCS, MMF On IST
Lungs
— — — — —
Severe 100 Skin pCS, GCS, MMF Resolved
207 Liver FK506, GCS Resolved
256 Mouth FK506, GCS Resolved
323 Eye FK506 Resolved
Moderate 100 Mouth-skin-liver pCS, GCS, MMF On IST
Mild 139 Liver pCS, GCS Resolved
— — — —
Moderate 112 Skin-liver pCS, GCS Resolved
Severe 111 Skin pCS, GCS On IST
134 Mouth
232 Liver
Moderate 66 Mouth-liver pCS, GCS Resolved
ontinuation of prophylactic cyclosporine; GCS, glucocorticosteroids; CS,
t.
Table 4. Cytomegalovirus and Other Significant Infections Observed after Hematopoietic Cell Transplantation from an HLA-
Mismatched Familial Donor after Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin*
UPN
Pretransplant CMV IgG
CMV Reactivation
(Days after HCT)
CMV+ Cells per 200,000
Preemptive
Treatment
CMV Disease
(Days after
HCT)
Significant Infections Other Than
CMV (Days after HCT)Patient Donor Initial Maximum
346 + + Yes (35) 3 3 Yes — —
358 + + Yes (35) 64 64 Yes — —
359 + + No — — — — Perianal abscess (14)
390 + + No — — — — Cutaneous varicella-zoster infection (295)
395 + + No — — — — Cutaneous varicella-zoster infection (569)
431 + + Yes (21) 4 4 Yes — —
435 + + No — — — — Sepsis, Klebsiella pneumonia (11)
446 + + No — — — — —
454 + + Yes (32) 2 2 Yes Yes (36) Back muscle abscess, Nocardia farcinica
(105); Pneumonia (146)
463 + + Yes (60) 6 6 Yes Yes (64) —
465 + + Yes (32) 1 8 Yes — Pneumonia, Pneumocystis carinii (110)
479 + 2 No — — — — —
PNU + + Yes (47) Unknown Unknown Yes — Cutaneous varicella-zoster infection (110)
495 + + Yes (44) 1 22 Yes — Sepsis, Klebsiella pneumoniae (61); Sepsis,
Stenotrophomonas maltophilia (82);
Cutaneous varicella-zoster infection (125)
518 + + Yes (16) 6 11 Yes — Pseudomembranous colitis (D28)
523 + + Yes (50) 6 6 Yes — —
528 + + Yes (35) 1 6 Yes — —
546 + + Yes (37) 1 13 Yes — Pneumonia (12); Sepsis, Staphylococcus
aureus (12)
549 + + No — — — — Pneumonia (37); Cutaneous varicella-zoster
infection (230)
551 + + Yes (19) 2 2 No — Central line sepsis, Enterobacter cloacae (44)
568 + + Yes (61) 1 1 No — Cutaneous varicella-zoster infection (313)
576 + + Yes (43) 1 1 No — —
582 + + Yes (34) 4 26 Yes — —
590 + + No — — — — —
592 + + Yes (20) 1 6 No — —
593 + + No — — — — —
606 + + Yes (35) 1 4 No — —
612 + + No — — — — Sepsis (10)
615 + + Yes (40) 1 3 No — —
617 + + No — — — — Pneumonia (0); Sepsis, Stenotrophomonas
maltophilia (0)
618 + + Yes (62) 8 8 No — Cutaneous varicella-zoster infection (177)
UPN indicates unique patient number; CMV, cytomegalovirus; HCT, hematopoietic cell transplantation.
*Posttransplant infectious episodes observed before the occurrence of underlying leukemia or myelodysplastic syndrome are described.
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83%).
In total, 4 patients in the study died because of
transplantation-related causes with a cumulative inci-
dence of TRM of 13% (95% CI, 5%-33%). None in
the study experienced late opportunistic infections or
posttransplant lymphoproliferative disorder.Immune Recovery
The patients in our study experienced a prompt re-
covery of their lymphocyte counts. In 15 cases, with
a survival longer than 3 months after HCT and with-
out recurrence/persistence of their disease and no
aGVHD over grade 1, there was an initial decrease
in the CD41 and CD81 cell counts 1 month after
HCT. These counts, however, recovered by 2 months
and the mean CD41 and CD81 cell counts were over
250/mL and 1000/mL, respectively, until 12 months af-
ter HCT (Figure 3A-C). CD161/561NK cells, on theother hand, showed no initial decrease but showed in-
creasing counts beginning at 1 month with a peak at 2
months (Figure 3D). In 4 patients with grade 2-4
aGVHD after HCT, the lymphocyte subset counts
were lower until 6 months. Three patients who recov-
ered from aGVHD, however, showed the comparable
lymphocyte subset counts by 12 months after HCT.DISCUSSION
The purpose of our current study was to investi-
gate the feasibility of HCT from an HLA-mismatched
familial donor without ex vivo depletion of donor T
cells after conditioning with busulfan in reduced
dose, fludarabine, and ATG, 1 of the more widely
used and relatively less toxic conditioning regimens.
Our study showed that this transplantation approach
was feasible with a high rate of donor cell engraftment
and without excessive GVHD and TRM. RIC with
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Biol Blood Marrow Transplant 15:61-72, 2009 69HLA-Mismatched HCTafter RIC Containing ATGbusulfan, fludarabine, and ATG showed sufficient im-
munosuppression to enable consistent engraftment of
donor hematopoietic cells across the HLA-major mis-
match/haploidentical barriers in adult patients. Ex-
cluding 3 patients who either died or relapsed with
leukemia very early after HCT, all the remaining 28
patients achieved an ANC over 500/mL on median
day 16.5. Furthermore, over 90% of our study patientsC
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chimerism was durable, and none of the patients expe-
rienced secondary graft failure. In addition to a consis-
tent donor cell engraftment, cumulative incidences of
grade 2 to 4 aGVHD and moderate to severe cGVHD
were found to be 19% and 20%, respectively, which
are no higher than the frequencies for theseC
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neic HCT. Only 4 patients in our study died of trans-
plantation-related causes, giving an overall TRM of
13%.
The total i.v. doses of busulfan and fludarabine,
contained in the preparative regimen used in our study,
were 6.4 mg/kg and 180 mg/m2, respectively, which
were similar to the doses of these same agents used
in other RIC protocols [17,18]. The total dose of
ATGwas 12 mg/kg for rabbit ATG (Thymoglobulin),
which is higher than those of other reported regimens
[18,27,28]. ATG was given until the day before the in-
fusion of donor cells. The hematopoietic cell grafts
were obtained from the peripheral blood after mobili-
zation with G-CSF and transplanted without ex vivo
depletion of T cells. Therefore, quite large numbers
of donor T cells and CD341 cells were infused (me-
dian 4.7  108/kg and 6.8  106/kg, respectively).
The findings of our current study are in agreement
with a previous study of 26 patients by Ogawa et al.
[28] using RIC with orally administered busulfan (8
mg/kg), fludrabine, and rabbit ATG (8 mg/kg, from
days 24 to 21) for HCT from haploidentical donors.
GVHD prophylaxis in this study included tacrolimus
and methylprednisolone. The mean number of HLA
antigen differences between the donors and patients
in our study and this study were similar (2.47 of 6
and 2.46 of 6, respectively, for GVH direction and
2.40/6 and 2.19/6, respectively, for rejection direc-
tion). As in our current report, a consistent neutrophil
engraftment (25 of 26 patients) and an early complete
donor cell chimerism (25 of 25 patients at 2 weeks) was
observed. Grade 2-4 aGVHD and cGVHD were not
frequent (20% and 25%, respectively). In another pre-
vious study of 49 patients that investigated the role of
RIC in mismatched HCT, the conditioning regimen
contained fludarabine, cyclophosphamide, and alem-
tuzumab (100 mg), a humanized monoclonal antibody
against CD52 [29]. In agreement with our current
findings, grade 2-4 aGVHD and cGVHD were not
frequent (16% and 14% of patients, respectively).
However, there were 7 patients (14%) reported who
experienced primary or secondary graft failure. Donor
chimerism was achieved more slowly with a median
donor DNA of 72% at 0.5 months after HCT.
The consistent engraftment with low GVHD we
observed following HLA-mismatched HCT after
RIC in our present study is intriguing and in contrast
to the traditional concept of allogeneic HCT, where
an increasing number of HLA disparities is considered
as 1 of the most important determinants for increasing
graft failure, as well for increasing GVHD [1]. De-
creased tissue damage induced by RIC, as opposed to
myeloablative conditioning,may lead to reduced release
of tissue antigens and proinflammatory cytokines,
thereby favoring a posttransplant host environment
with decreased triggering of aGVHD. In addition,changes in the conditioning regimen given prior to
allogeneic HCT can increase the contents and func-
tions of regulatory T cells, resulting in an immune-
modulatory rather than an immune-stimulating
environment after HCT [33]. A high engraftment
rate, along with low acute GVHD, has also been ob-
served after HCT across the barrier of major histo-
compatibility complex (MHC) genes after RIC in an
SLA-haploidentical transplantationmodel [19]. Taken
together, these findings suggest that the role of dispar-
ities in major MHC antigens as a determinant of
adverse outcomes of HCT may vary according to the
intensity and type of conditioning regimens.
Antibodies against T cells, either polyclonal or
monoclonal, have been used commonly as a part of
the conditioning regimen in clinical trials of HLA-
mismatched HCT [11,13,28,29]. At present, it is not
possible to ascertain which of the components of our
RIC, the reduced intensity of the conditioning regi-
men itself, the addition of high-dose of ATG, or the
combination of the 2, played the most important role
in generating the favorable HCT outcomes in our cur-
rent study. Higher rates of grade 2-4 aGVHD (40%),
cGVHD (55%), and TRM (22% at 2 years) were
observed in a previous study, however, when ATG
(Thymoglobulin, 10 mg/kg) was administered to 135
patients receiving HLA-mismatched HCT along
with dose-intensive conditioning regimen containing
busulfan (12 mg/kg orally), cyclophosphamide,
methyl-CCNU, and cytarabine [11]. These findings
suggested that the reduced intensity of conditioning it-
self may have played at least a part of the role in reduc-
ing the frequencies of GVHD and TRM we observed
herein.
It is noteworthy that we observed no significant
delays in global immune recovery after HCT in our
present patient cohort. We also observed a faster lym-
phocyte subset counts recovery when compared with
previous studies employing ex vivo T cell depletion
[10] or incorporating alemtuzumab as a part of the
conditioning protocol [13,29].
The importance of the concept of feto-maternal
immune tolerance for the selection of an HLA-mis-
matched familial donor remains to be determined
[15]. In the series of 135 patients who received HLA-
mismatched familial donor HCT, the donor type did
not affect the HCT outcome [11]. In our study, among
3 male patients who received the grafts from their off-
spring, such that no feto-maternal immune tolerance
existed between the patient and the donor, 1 died be-
cause of grade IV aGVHD, whereas the other 2 expe-
rienced successful engraftment with only 1 of the 2
having moderately severe cGVHD, which resolved af-
ter treatment (UPN 528).
In conclusion, we show in our present study that
HCT from an HLA-mismatched familial donor is fea-
sible after RIC with busulfan, fludarabine, and ATG.
Biol Blood Marrow Transplant 15:61-72, 2009 71HLA-Mismatched HCTafter RIC Containing ATGTherefore, this treatmentmodalitymay play an impor-
tant role in future treatments of high-risk hematologic
malignancies, as well of bone marrow failure syn-
drome, when an HLA-matched donor is not available
or when allogeneic HCT is needed urgently. More-
over, because of the less intense nature of our condi-
tioning regimen, elderly patients and patients who
have been treated a great deal, particularly with a previ-
ous HCT, can also be treated with our transplantation
regimen. Further studies are needed to determine
whether a stronger graft-versus-leukemia effect would
result from HLA-mismatched HCT compared with
HLA-matched HCT, as has been suggested in a mu-
rine model [34]. Finally, our transplantation approach
may have utility in investigational cancer immunother-
apy protocols, where natural killer cells from an HLA-
mismatched familial donor can be given after HCT for
the treatment of advanced malignancies [35].ACKNOWLEDGMENTS
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